CG Oncology’s (CGON) Overweight Rating Reaffirmed at Cantor Fitzgerald

CG Oncology (NASDAQ:CGON)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga reports. They presently have a $75.00 price target on the stock. Cantor Fitzgerald’s target price points to a potential upside of 106.78% from the stock’s previous close.

Several other equities analysts have also recently commented on the stock. Morgan Stanley initiated coverage on shares of CG Oncology in a research note on Tuesday, February 20th. They set an “overweight” rating and a $55.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a research report on Thursday, April 4th. Finally, The Goldman Sachs Group assumed coverage on shares of CG Oncology in a research note on Tuesday, February 20th. They issued a “neutral” rating and a $42.00 target price for the company.

CG Oncology Stock Performance

Shares of NASDAQ CGON traded down $3.23 during trading hours on Thursday, hitting $36.27. 2,443,166 shares of the company’s stock were exchanged, compared to its average volume of 390,521. The firm has a 50-day moving average of $39.63. CG Oncology has a 1-year low of $28.55 and a 1-year high of $50.23.

Hedge Funds Weigh In On CG Oncology

A hedge fund recently bought a new stake in CG Oncology stock. BNP Paribas Financial Markets bought a new stake in CG Oncology, Inc. (NASDAQ:CGON) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,198 shares of the company’s stock, valued at approximately $492,000. 26.56% of the stock is currently owned by institutional investors.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.